SHANGHAI -- China approved the country's first domestically made COVID-19 vaccine on Thursday, paving the way for mass inoculation and recognition overseas.
Developed by the Beijing Biological Products Institute under China National Pharmaceutical Group, or Sinopharm, the vaccine showed 79.34% efficacy and a 99.52% antibody positive conversion rate in Phase 3 clinical trial results, the institute announced a day earlier.
